Drug Type Small molecule drug |
Synonyms 3-(4-hydroxyphenyl)-2H-chromen-7-ol, Dehydroequol, Haginin E + [4] |
Target |
Mechanism S1PRs antagonists(Sphingosine 1-phosphate receptor antagonists), SPHK2 inhibitors(Sphingosine kinase 2 inhibitors), SPK 1 inhibitors(Sphingosine kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC15H12O3 |
InChIKeyZZUBHVMHNVYXRR-UHFFFAOYSA-N |
CAS Registry81267-65-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fallopian Tube Carcinoma | Phase 3 | US | 01 Oct 2006 | |
Fallopian Tube Carcinoma | Phase 3 | AU | 01 Oct 2006 | |
Fallopian Tube Carcinoma | Phase 3 | BE | 01 Oct 2006 | |
Fallopian Tube Carcinoma | Phase 3 | IT | 01 Oct 2006 | |
Fallopian Tube Carcinoma | Phase 3 | PL | 01 Oct 2006 | |
Fallopian Tube Carcinoma | Phase 3 | ES | 01 Oct 2006 | |
Fallopian Tube Carcinoma | Phase 3 | GB | 01 Oct 2006 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | US | 01 Oct 2006 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | AU | 01 Oct 2006 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | BE | 01 Oct 2006 |
Phase 1/2 | 21 | EBRT+NOX66 (Part 1: Dose Cohort 1: NOX66 800 mg) | ffnfyzcfiy(hfxdckyslu) = qhjqkkdrbn ckeqguzwmb (azelxzqidy, vvplzxpbji - wrbeyhcpkg) View more | - | 18 Jun 2024 | ||
EBRT+NOX66 (Part 1: Dose Cohort 2: NOX66 1200 mg) | ffnfyzcfiy(hfxdckyslu) = mlxkvdkgqu ckeqguzwmb (azelxzqidy, mhwebiwkqq - estuwaevfj) View more | ||||||
Phase 1/2 | 11 | nivolumab+NOX66 | rtiavikhkw(hqsuaatqli) = The most common AE was local perineal irritation, readily managed with topical corticosteroid cream. plxbxdsqaw (zatcdixbar ) | Positive | 31 May 2023 | ||
Phase 1 | 25 | NOX66 + radiation therapy | ilgonnhdmq(zumyobswza) = TEAEs considered related to NOX66 alone were mild (Grade 1) cases of dry mouth and oral mucositis; mild (Grade 1) fatigue was considered related to both NOX66 and radiation. None of the 21 Grade ≥3 TEAEs were considered related to NOX66 dpihjxzzmf (kjfhiethke ) | Positive | 25 May 2020 | ||
Phase 1 | 25 | palliative radiotherapy+Veyonda | tkgkdkqwpu(eygwgbtxvh) = zejbsykedd pmsofvqkcn (pzreqnhzic ) View more | Positive | 02 Dec 2019 | ||
Not Applicable | - | fpcjrllhbl(lzycphcjqc) = Phenoxodiol also inhibited the Akt pathway by causing dephosphorylation of Akt. This inhibition of the Akt pathway inhibited expression of the apoptosis inhibitor FLIP and thus led to renal cancer apoptosis bmbtwoxahf (ohmmiyzfuu ) View more | - | 01 Apr 2017 | |||
Phase 3 | 142 | yilvixciod(hmwijachkv) = gxlrxymeok anliojqlmd (wescsztwdf, 11.1 - 21.0) View more | Negative | 01 Jan 2014 | |||
Placebo + AUC2-carboplatin | yilvixciod(hmwijachkv) = ejvbnefhjo anliojqlmd (wescsztwdf, 13.1 - 33.4) View more | ||||||
Phase 2 | 65 | lrmqlyqkbp(avmrsqjgyw) = ocijpsnlgn fszuyarvfa (bgzewlggmj ) | - | 01 May 2011 | |||
lrmqlyqkbp(avmrsqjgyw) = fxpvmgjwxb fszuyarvfa (bgzewlggmj ) | |||||||
Phase 2 | - | (Castrate-resistant prostate cancer patients) | sfywtgilfh(eeeuqfusql) = frjopenvkj jzsrltkjbi (lgehmxhnbf ) | - | 20 May 2010 |